<SEC-DOCUMENT>0001181431-12-040575.txt : 20120712
<SEC-HEADER>0001181431-12-040575.hdr.sgml : 20120712
<ACCEPTANCE-DATETIME>20120712184522
ACCESSION NUMBER:		0001181431-12-040575
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20120710
FILED AS OF DATE:		20120712
DATE AS OF CHANGE:		20120712

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Anderson Joseph
		CENTRAL INDEX KEY:			0001475259

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-176897
		FILM NUMBER:		12960159

	MAIL ADDRESS:	
		STREET 1:		38 JERMYN STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			SW1Y 6DN

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rrd350910.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2012-07-10</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000897448</issuerCik>
        <issuerName>AMARIN CORP PLC\UK</issuerName>
        <issuerTradingSymbol>AMRN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001475259</rptOwnerCik>
            <rptOwnerName>Anderson Joseph</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O AMARIN PHARMA, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1430 ROUTE 206, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>BEDMINSTER</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07921</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>14.40</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2012-07-10</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>30000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2022-07-10</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>30000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>30000</value>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The stock option was granted to Joseph Anderson (the &quot;Reporting Person&quot;) on July 10, 2012 pursuant to and in accordance with the Issuer's non-employee director compensation policy and the Issuer's 2011 Stock Incentive Plan, as amended, and will vest on the first anniversary of the grant date.</footnote>
        <footnote id="F2">The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.</footnote>
        <footnote id="F3">The Reporting Person is a member of Abingworth LLP (&quot;ALLP&quot;). ALLP is the investment manager to a number of investment funds that include Abingworth Bioventures V L.P. (&quot;ABV V&quot;) and Abingworth Bioventures V Co-Invest Growth Equity Fund LP (&quot;AGE&quot;) (together, the &quot;Abingworth Funds&quot;). Under an agreement between the Reporting Person and ALLP, of the 30,000 options reported herein, the Reporting Person is deemed to hold 12,000 of the options for the benefit of ABV V, 12,000 of the options for the benefit of AGE, and 4,200 of the options for the benefit of ALLP (such 28,200 options, collectively, the &quot;Abingworth Options&quot;), and any Ordinary Shares issuable upon exercise of the Abingworth Options, for the benefit of ALLP on behalf of itself and the Abingworth Funds, and must exercise the Abingworth Options solely upon the direction of ALLP.</footnote>
        <footnote id="F4">The Reporting Person's interest in the securities reported herein is limited to the extent of his pecuniary interest, if any, therein. This report shall not be deemed an admission that the Reporting Person, ALLP, each Abingworth Fund or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Frederick Ahlholm, by power of attorney</signatureName>
        <signatureDate>2012-07-12</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
